Overview

• In a randomized double-blind, placebo-controlled study of 201 healthy adults, participants received 5 mg/kg/day of oral CBD or placebo over 28 days.
• Aminotransferase levels rose above three times the normal limit in about 5% of CBD users, signaling potential liver cell damage.
• Seven volunteers dropped out after showing clinical signs of drug-induced liver injury, with enzyme levels returning to normal one to two weeks after stopping CBD.
• Trial data indicate women may face higher susceptibility to CBD-induced liver enzyme elevations than men.
• Researchers are urging medical practitioners to screen for CBD use in liver tests and regulators are weighing tighter oversight of unregulated CBD supplements.